Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corgenix Medical, a developer and marketer of diagnostic test kits, has received notification of US Patent Office approval for technology to which Corgenix holds exclusive worldwide licensing rights outside of Japan.
Subscribe to our email newsletter
The patent, method for measuring oxidized LDL-CRP complex and measurement kit, describes the binding of oxidized low-density lipoprotein (oxLDL) with C-reactive protein (CRP) resulting in oxLDL/CRP (CRP-AtherOx) complex formation, and the immunoassay method for measuring these complexes in blood. The technology is incorporated in the company’s AtherOx product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease.
The latest patent adds to previous US patents which describe the specific interaction of B2-glycoprotein I with the oxLDL leading to the formation of oxLDL/B2-glycoprotein I complexes.
Douglass Simpson, president and CEO of Corgenix, said: “We are very pleased to announce this important addition to our IP portfolio. We have one product already cleared by the FDA and several products in the later stages of the development pipeline with FDA submission expected in the next year or so.”
In all countries where the use of products employing this technology has not been cleared, the products shall not be used for diagnostic use as the performance characteristics have not been established, the company said.